Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2007-02-20
2007-02-20
Zara, Jane (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C435S091310, C435S455000, C435S458000, C536S023100, C536S024500
Reexamination Certificate
active
10009420
ABSTRACT:
Highly specific hammerhead ribozymes are provided that human target estrogen receptor mRNA. These ribozymes, designated RZ1 through RZ7 provide predictable mRNA cleavage products. Methods for inhibiting estrogen-dependent tumor growth, such as that characteristic of breast cancer, are also provided employing these ribozymes. One or both of the ribozymes may be used together or separately with equal efficiency. The ribozymes possess a sequence region with a catalytic core that provides the attributed catalytic activity to these ribozymes.
REFERENCES:
patent: 5496698 (1996-03-01), Draper et al.
patent: 5525468 (1996-06-01), McSwiggen
patent: 5834440 (1998-11-01), Goldenberg et al.
patent: WO 99/54459 (1999-10-01), None
patent: WO 00/74485 (2000-12-01), None
Amarzguioui and Prydz, “Hammerhead Ribozyme Design and Application,”CMLS, 54:1175-1202, 1998.
Branch, “A Good Antisense Molecule is Hard to Find,”TIBS, 23:45-50, 1998.
Chen et al., “Catalytic Cleavage of the Androgen Receptor Messenger RNA and Functional Inhibition of Androgen Receptor Activity by a Hammerhead Ribozyme,”Mol. Endocrinol., 12(10):1558-1566, 1998.
Chen, “Molecular Strategies for Selective Inhibition of Androgen Receptor Gene Expression,”A Dissertation presented to the Faculty of The University of Texas Graduate School of Biomedical Sciences at San Antonio in partial fulfillment of the requirements for the Degree of Doctor of Philosophy in Cellular and Structural Biology, Mar. 1997; Also, vol. 58/03-B of Dissertation Abstracts International, p. 1103, 1997.
Chen and Roy, “Specific Inactivation of the Androgen Receptor Messager RNA by a Hammerhead Ribozyme,”Premier Event in 10thInternational Congress of Endocrinol., 10:87, 1996.
Cotton and Birnstiel, “Ribozyme Mediated Destruction of RNAin vivo,” EMBOJ., 8(12):3861-3866, 1989.
Forster and Symons, “Self-Cleavage of Plus and Minus RNAs of a Virusoid and a Structural Model for the Active Sites,”Cell, 49:211-220, 1987.
Haseloff and Gerlach, “Simple RNA Enzymes with New and Highly Specific Endoribonuclease Activities,”Nature, 334:585-591, 1988.
James, “Towards Gene-Inhibition Therapy; A Review of Progress and Prospects in the Filed of Antiviral Antisense Mucleic Acids and Ribozymes,”Antisense Nucleic Acids and Ribozymes, 2(4):191-214, 1991.
Klefstrom et al., “c-Myc Induces Cellular Susceptibility to the Cytotoxic Action of TNF-α,”p0EMBO J., 13(22):5442-5450, 1994.
Kobayashi et al., “Reversal of Drug Sensitivity in Multidrug-Resistant Tumor Cells by an MDR1 (PGY1) Ribozyme,”Cancer Research, 54:1271-1275, 1994.
Lavrovsky et al., “Ribozyme-mediated Cleavage of the Estrogen Receptor Messenger RNA and Inhibition of Receptor Function in Target Cells,”Mol. Endocrinol., 13(6):925-934, 1999.
L'Huillier et al., “Efficient and Specific Ribozyme-Mediated Reduction of Bovine α-Lactalbumin Expression in Double Transgenic Mice,”Proc. Natl. Acad. Sci. USA, 93:6698-6703, 1996.
Marshall, “Gene Therapy's Growing Pains,”Science, 269:1050-1055, 1995.
Marshall, “Gene Therapy on Trial,”Science, 288:951-957, 2000.
Milner et al., “Selecting Effective Antisense Reagents on Combinatorial Oligonucleotide Arrays,”Nature Biotechnology, 15:537-541, 1997.
Pyle, “Ribozymes: A Distinct Class of Metalloenzymes,”Science, 261:709-714, 1993.
Sarver et al., “Ribozymes as Potential Anti-HIV-1 Therapeutic Agents,”Science, 247:1222-1225, 1990.
Scanlon et al., “Ribozyme-Mediated Cleavage of c-fos mRNA Reduces Gene Expression of DNA Synthesis and Metallothionein,”Proc. Natl. Acad. Sci. USA, 88:10591-10595, 1991.
Stull and Szoka, “Antigene, Ribozyme and Aptamer Nucleic Acid Drugs: Progress and Prospects,”Pharmaceutical Research, 12(4):465-483, 1995.
Suzuki et al., “Adenovirus-Mediated Ribozyme Targeting of HER-2neu Inhibitsin vivoGrowth of Breast Cancer Cells,”Gene Therapy, 7:241-248, 2000.
Turley et al., “Vitamin E Succinate Induces Fas-Mediated Apoptosis in Estrogen Receptor-Negative Human Breast Cancer Cells,”Cancer Research, 57:881-890, 1997.
Uhlenbeck, “A Small Catalytic Oligoribonucleotide,”Nature, 328596-60, 1987.
Chatterjee Bandana
Chen Shuo
Lavrovsky Yan
Roy Arun K.
Song Chung S.
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Zara Jane
LandOfFree
Estrogen receptor site-specific ribozymes and uses thereof... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Estrogen receptor site-specific ribozymes and uses thereof..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Estrogen receptor site-specific ribozymes and uses thereof... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3818266